Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

100%

8 trials in Phase 3/4

Results Transparency

100%

7 of 7 completed trials have results

Key Signals

7 with results

Enrollment Performance

Analytics

Phase 3

7(87.5%)

Phase 4

1(12.5%)

8Total

Phase 3(7)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT05780437Phase 3Completed

AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Role: collaborator

NCT04969250Phase 4Completed

Vaccination for Recovered Inpatients With COVID-19 (VATICO)

Role: collaborator

NCT05780541Phase 3Terminated

PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Role: collaborator

NCT05780463Phase 3Completed

MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Role: collaborator

NCT05780424Phase 3Completed

BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Role: collaborator

NCT05780281Phase 3Completed

VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Role: collaborator

NCT05780268Phase 3Completed

LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Role: collaborator

NCT04501978Phase 3Completed

ACTIV-3: Therapeutics for Inpatients With COVID-19

Role: collaborator

All 8 trials loaded